Anakinra effective against macrophage activation syndrome
Treatment with anakinra appears beneficial to children with secondary haemophagocytic lymphohistiocytosis (HLH)/macrophage activation syndrome (MAS), especially when administered early in the disease course and to those who have an underlying rheumatic disease, as shown in a study.
